Search

Displaying results 5271 - 5280 of 8698 in total
  1. Drug

    IGN101

    go.drugbank.com/drugs/DB06500
    Experimental

    IGN101 is an antibody-based cancer vaccine directed against epithelial cancers. It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.

  2. Drug

    Metiamide

    go.drugbank.com/drugs/DB08805
    Experimental

    Metiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.

  3. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks

    Categories: Calcitonin Gene-Related Peptide Receptor Antagonists
  4. Drug

    ZD4407

    go.drugbank.com/drugs/DB06539
    Experimental

    The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor. … It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003

  5. Drug

    Lonicera caprifolium flower

    go.drugbank.com/drugs/DB14280
    Approved

    It is not an approved drug.

  6. Drug

    Larix sibirica wood

    go.drugbank.com/drugs/DB14289
    ApprovedWithdrawn

    It is not an approved drug.

  7. Drug

    Apricot kernel oil

    go.drugbank.com/drugs/DB14324
    Approved

    It is not an approved drug.

  8. Drug

    Azadirachta indica leaf

    go.drugbank.com/drugs/DB14352
    Approved

    It is not an approved drug.

  9. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. … It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.

  10. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis